RGNX$13.76
$13.82
Chart
Performance
Key Stats
AI RGNX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyREGENXBIO Inc. shows strong fundamentals in the gene therapy space with a promising pipeline, but its recent performance and current valuation warrant a balanced approach. The company is well-positioned for long-term growth, though near-term price action may be volatile.
Thematic
The company operates within the rapidly expanding gene therapy market, driven by advancements in biotechnology and increasing demand for novel treatments for genetic disorders.
Fundamental
REGENXBIO Inc. demonstrates a solid financial foundation with a strong balance sheet and growing revenue potential, despite current net losses typical of a clinical-stage biotechnology company.
Technical
The stock is trading within its 52-week range, showing some recent positive momentum but facing overhead resistance. Key moving averages suggest a mixed short-term outlook.
| Factor | Score |
|---|---|
| Gene Therapy Market Growth | 85 |
| Pipeline Development | 80 |
| Biotechnology Innovation | 75 |
| Partnerships & Collaborations | 70 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 20 |
| Growth | 40 |
| Balance Sheet Health | 75 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown positive performance over the 5-day (+6.18%), 1-month (+8.46%), and 6-month (+18.64%) periods, indicating recent upward momentum.
Improving Cash Position
Cash equivalents have increased from $34.52 million in Q4 2023 to $57.53 million in Q4 2024, suggesting better short-term financial flexibility.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses across all reported periods (e.g., -$227.1 million in 2024, -$263.5 million in 2023). The EPS figures show negative estimates and reported values, indicating ongoing unprofitability.
Negative EPS Surprises
Several quarterly EPS reports show negative surprises (e.g., -75.14% in Q2 2025, -12.55% in Q1 2024), indicating that actual earnings have been worse than analyst expectations.
Calendar
July 2025
30
Next Earnings Date
H: $-0.75
A: $-1.05
L: $-1.34
H: 142.89M
A: 40.87M
L: 20.00M
Profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Seasonals
Price Target
31.42 USD
The 39 analysts offering 1 year price forecasts for RGNX have a max estimate of 52.00 and a min estimate of 13.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct collaboration with Regenxbio on RGX-314, an AAV gene therapy for wet AMD, signifying a strategic partnership in RGNX's lead program.
Weight: 90
A global pharmaceutical leader with a robust gene therapy presence, notably through its acquisition of AveXis and commercialization of Zolgensma, an AAV gene therapy, making it a major competitor and benchmark in the AAV space.
Weight: 88
Acquired Spark Therapeutics, a pioneering AAV gene therapy company with multiple approved therapies, establishing Roche as a significant player and competitor in the gene therapy landscape.
Weight: 85
A leading gene therapy company focused on rare neuromuscular diseases, with an approved gene therapy for Duchenne Muscular Dystrophy, making it a key peer in rare disease gene therapy.